Travere Therapeutics (TVTX) Profit After Tax (2011 - 2026)

Travere Therapeutics (TVTX) has 16 years of Profit After Tax data on file, last reported at -$36.6 million in Q1 2026.

• Quarterly Profit After Tax rose 11.22% year-over-year to -$36.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.9 million (up 90.71% YoY) and the FY2025 annual result came in at -$25.5 million, up 92.02% from the prior year.
• Profit After Tax declined to -$36.6 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $25.7 million in Q3 2025 to a low of -$136.1 million in Q1 2024.
• A 5-year average of -$62.7 million and a median of -$70.4 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2022 — Profit After Tax tumbled 135.87% — and 2025, when it jumped 147.43%.
• Tracing TVTX's Profit After Tax over 5 years: stood at -$85.6 million in 2022, then decreased by 3.46% to -$88.6 million in 2023, then soared by 33.04% to -$59.3 million in 2024, then surged by 104.6% to $2.7 million in 2025, then plunged by 1441.22% to -$36.6 million in 2026.
• The last three Profit After Tax figures came in at -$36.6 million (Q1 2026), $2.7 million (Q4 2025), and $25.7 million (Q3 2025), per Business Quant data.